Thursday, October 19, 2017

Forty Seven Finds $75M For Cancer Drugs

Menlo Park-based Forty Seven, a developer of oncology drugs based on antibodies, has raised $75M in a Series B funding, the company said this week. The funding was led by Wellington Management Company, and also included Clarus Ventures, Lightspeed Venture Partners, Sutter Hill Ventures, and GV (Google Ventures). Forty Seven says it is developing an antibody, Hu5F9‐G4, which "takes the brakes off macrophages". The company is in Phase 1b/2 trial in patients with solid tumors, leukemia, or lymphoma. More information »